Investigations of a rabbit (Oryctolagus cuniculus) model of Systemic Lupus Erythematosus (SLE), BAFF and its receptors

PLoS ONE

Volumn 4, Issue 12, 2009, Pages

  Yang, Jiahui ^a   Pospisil, Richard ^a   Ray, Satyajit ^a   Milton, Jacqueline ^a   Mage, Rose G ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; BETA 2 MICROGLOBULIN; MESSENGER RNA; PEPTIDE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BASOPHIL; CELL SURVIVAL; CONTROLLED STUDY; EOSINOPHIL COUNT; FEMALE; FLOW CYTOMETRY; HUMORAL IMMUNITY; IMMUNIZATION; LEUKOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MALE; NEUTROPHIL COUNT; NONHUMAN; ORYCTOLAGUS CUNICULUS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RABBIT; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LEUKOCYTE; METABOLISM; PEDIGREE; POLYMERASE CHAIN REACTION;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

ANIMALS; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; B-CELL ACTIVATING FACTOR; B-CELL ACTIVATION FACTOR RECEPTOR; BETA 2-MICROGLOBULIN; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; IMMUNIZATION; LEUKOCYTES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PEDIGREE; PEPTIDES; POLYMERASE CHAIN REACTION; RABBITS; RNA, MESSENGER; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN;

EID: 77949506955     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008494     Document Type: Article

References (38)

1. Ardoin SP, Pisetsky DS (2008) Developments in the scientific understanding of lupus. Arthritis Res Ther 10: 218. Available: (http://arthritis-research.com/content/10/5/218).
2. Cancro MP, D'Cruz DP, Khamashta MA (2009) The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 119: 1066-1073.
3. Pego-Reigosa JM, Isenberg DA (2008) Systemic lupus erythematosus: pharma- cological developments and recommendations for a therapeutic strategy. Expert Opin Investig Drugs 17: 31-41.
4. Ding C, Foote S, Jones G (2008) B-cell-targeted therapy for systemic lupus erythematosus: an update. BioDrugs 22: 239-249.
5. Rai G, Ray S, Shaw RE, DeGrange PF, Mage RG, et al. (2008) Models of systemic lupus erythematosus: Development of autoimmunity following peptide immunizations of noninbred pedigreed rabbits. J Immunol 176: 660-667.
6. James JA, Gross T, Scofield RH, Harley JB (1995) Immunoglobulin epitope spreading and autoimmune disease after peptide immunization: Sm B/B9- derived PPPGMRPP and PPPGIRGP induce spliceosome autoimmunity. J Exp Med 181: 453-461.
7. DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, et al. (2001) A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 7: 1189-1193.
8. Diamond B, Kowal C, Huerta PT, Aranow C, Mackay M, et al. (2006) Immunity and acquired alterations in cognition and emotion: lessons from SLE. Adv Immunol 89: 289-320.
9. Puliyath N, Ray S, Milton J, Mage RG (2008) Genetic contributions to the autoantibody profile in a rabbit model of systemic lupus erythematosus (SLE). Vet Immunol Immunopathol 125: 251-267.
10. Treml JF, Hao Y, Stadanlick JE, Cancro MP (2009) The BLyS family: toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys 53: 1-16.
11. Sakurai D, Kanno Y, Hase H, Kojima H, Okumura K, et al. (2007) TACI attenuates antibody production costimulated by BAFF-R and CD40. Eur J Immunol 37: 110-118.
12. O'Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, et al. (2004) BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 199: 91-98.
13. Groom JR, Fletcher CA, Walters SN, Grey ST, Watt SV, et al. (2007) BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med 204: 1959-1971.
14. Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, et al. (2008) Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 58: 2453-2459.
15. Ju S, Zhang D, Wang Y, Ni H, Kong X, et al. (2006) Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus. Clin Biochem 39: 1131-1137.
16. Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, et al. (2008) Belimumab Study Group. Biologic activity and safety of belimumab, a neutralizing anti-B- lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus. erythematosus. Arthritis Res Ther 10: R109. (http://arthritis-Research.com/content/10/5/R109).
17. Cancro MP, D'Cruz DP, Khamashta MA (2009) The role of B lymphocyte stimulator [BLyS) in systemic lupus erythematosus. J Clin Invest 119: 1066-1073.
18. Ding C, Foote S, Jones G (2008) The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. BioDrugs 22: 239-249.
19. Yang J, Pospisil R, Mage RG (2009) Expression and localization of rabbit B-cell activating factor [BAFF) and its specific receptor BR3 in cells and tissues of the rabbit immune system. Develop Comp Immunol 33: 697-708.
20. Mage RG, Lanning D, Knight KL (2006) B cell and antibody repertoire development in rabbits: the requirement of gut-associated lymphoid tissues. Dev Comp Immunol 30: 137-153.
21. von Muhlen CA, Tan EM (1995) Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin in Arthritis Rheum 24: 323-358.
22. Servais G, Karmali R, Guillaume MP, Badot V, Duchateau J, et al. (2009) Anti DNA antibodies are not restricted to a specific pattern of fluorescence on HEp-2 cells. Clin Chem Lab Med 47: 543-549.
23. Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, et al. (2001) An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293: 2012-2013.
24. Shulga-Morskaya S, Dobles M, Walsh ME, Ng LG, MacKay F, et al. (2004): B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J Immunol 173: 2331-2341.
25. Ng LG, Ng C-H, Woehl B, Sutherland APR, Huo J, et al. (2006) BAFF costimulation of Toll-like receptor-activated B-1 cells. Eur J Immunol 36: 1837-1846.
26. Raman C, Knight KL (1992) CD5 B cells predominate in peripheral tissues of rabbit. J Immunol 149: 3858-3864.
27. Pospisil R, Obiakor H, Newman BA, Alexander C, Mage RG (2005) Stable expression of the extracellular domains of rabbit recombinant CD5: development and characterization of polyclonal and monoclonal antibodies. Vet Immunol Immunopathol 103: 257-267.
28. Pospisil R, Alexander CB, Obiakor H, Sinha RK, Mage RG (2006) CD5 B cells are preferentially expanded in rabbit appendix: the role of CD5 in B cell development and selection. Dev Comp Immunol 30: 711-722.
29. Pospisil R, Kabat J, Mage RG (2009) Characterization of rabbit CD5 isoforms. Mol Immunol 46: 2456-2464.
30. Darce JR, Arendt BK, Wu X, Jelinek DF (2007) Regulated expression of BAFF- binding receptors during human B cell differentiation. J Immunol 179: 7276-7286.
31. Carter RH, Zhao H, Liu X, Pelletier M, Chatham W, et al. (2005) Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus. Arthritis Rheum 52: 3943-3954.
32. Beutler B (2009) Microbe sensing, positive feedback loops, and the pathogenesis of inflammatory diseases. Immunol Rev 227: 248-263.
33. Seshasayee D, Valdez P, Yan M, Dixit VM, Tumas D, et al. (2003) Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 18: 279-288.
34. von Bulow GU, van Deursen JM, Bram RJ (2001) Regulation of the T- Independent Humoral Response by TACI. Immunity 14: 573-582.
35. Salzer U, Grimbacher B (2005) TACItly changing tunes: farewell to a yin and yang of BAFF receptor and TACI in humoral immunity? New genetic defects in common variable immunodeficiency. Curr Opin Allergy Clin Immunol 5: 504-509.
36. Mackay F, Schneider P (2008) TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties. Cytokine Growth Factor Rev 19: 263-276.
37. Ingold K, Zumsteg A, Tardivel A, Huard B, Steiner QG, et al. (2005) Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 201: 1375-1383.
38. Bossen C, Cachero TG, Tardivel A, Ingold K, Willen L, et al. (2008) TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. 111: 1004-1012.